Table 4.

Ongoing clinical trials of PARP inhibitors in pancreatic cancer.

Phase	Treatment arms	Setting	Treatment strategy	NCT number
I	NMS-03305293	Advanced/metastatic, relapsed/refractory solid tumours	Single agent, after progression on standard treatment	NCT04182516
I/II	Nanoliposomal Irinotecan + leucovorin + fluorouracil + rucaparib	Previously treated metastatic pancreatic, colorectal, gastroesophageal, biliary cancer	In combination with chemotherapy (as part of initial treatment)	NCT03337087
II	rucaparib	Solid tumours with deleterious mutations in homologous recombination repair genes	Initial treatment	NCT04171700
II	rucaparib	BRCA1-, BRCA2- or PALB2-mutant pancreatic cancer	Maintenance in BRCA1-, BRCA2- or PALB2-mutant pancreatic cancer without evidence of progression on platinum-based therapy	NCT03140670
II	niraparib	Unresectable and metastatic pancreatic cancer with deficiencies in HR DNA repair	Single agent after ≥2 lines	NCT03601923
II	niraparib	Metastatic pancreatic cancer after previous chemotherapy	Single agent after ≥2 lines	NCT03553004
II	niraparib + nivolumab versus niraparib + ipilimumab	Inoperable PDAC	Maintenance in inoperable PDAC and stability on platinum-based chemotherapy for ≥16 weeks without evidence of progressive disease	NCT 03404960

PDAC pancreatic ductal adenocarcinoma, HR homologous repair.